Watanabe Todd Franklin's Form 4 filing
Arcutis Biotherapeutics, Inc. (ARQT) · filed Mar 20, 2025
- Accession no.
- 0001787306-25-000048
- Filed
- Mar 20, 2025
- Trade date
- Mar 17, 2025
- Filing delay
- 3 daysLate
- Rule 10b5-1 plan
- Checked
This filing lists 1 non-derivative transaction. Open-market sales total $21.1K. It was filed 3 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Watanabe Todd FranklinCIK 0001801061 | Director, Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 17, 2025 | Common Stock | SSaleDisposed | −1,200 | $17.61F2 | −$21,132 | 928,914 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $17.5300 to $17.6600, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
Remarks
Reporting Person's title: President and Chief Executive Officer